Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?

Published:2019-05 Issue: Volume:113 Page:28-31
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bayle Arnaud^ORCID,Besse Benjamin,Annereau Maxime,Bonastre Julia^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference13 articles.

1. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer;Brahmer;N Engl J Med,2015

2. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N Engl J Med,2015

3. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;Lancet Lond Engl,2014

4. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

5. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer;Long;Ann Oncol,2018

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Budget impact models for lung cancer interventions: A systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09

2. Exploring the Potential of Nano Drug Delivery Systems in Non-Small Cell Lung Cancer Treatment: Recent Developments and Perspectives;Current Drug Therapy;2024-03-01

3. Dozens of precision cancer drugs tested at lower doses to reduce side effects and cut costs;Nature Medicine;2024-03

4. Rationalizing a prospective coupling effect of cannabinoids with the current pharmacotherapy for melanoma treatment;WIREs Mechanisms of Disease;2023-11-03

5. Vers une dé-escalade des traitements par immunothérapie des CBNPC avancés : pourquoi, comment ?;Revue des Maladies Respiratoires Actualités;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3